medigraphic.com
ISSN 1527-3172 (Electronic)

2008, Number 2

<< Back Next >>

MEDICC Review 2008; 10 (2)

Prevalence of obesity and its association with chronic kidney disease, hypertension and diabetes mellitus. Isle of Youth Study (ISYS), Cuba

Herrera VR, Almaguer LM, Chipi CJ, Toirac CX, Martínez SO, Castellanos RO, Bacallao GJ, Licourt PRM, Mulet PP, Diéguez PL, Velásquez BI, Hernández RMC, Caballero OW, Urra GP, Rodríguez TN

Language: English
References: 42
Page: 14-20
PDF size: 262.13 Kb.


ABSTRACT

Introduction Obesity is a social disease constituting a global pandemic. It is present in 90% of diabetic and 65% of hypertensive patients. It is associated with cardiometabolic syndrome and with damaging physiopathological mechanisms, particularly for the vascular system and the kidneys. On Cuba’s Isle of Youth, a community-based epidemiological study of chronic kidney disease (CKD), hypertension (HTN), diabetes mellitus (DM) and cardio-cerebral vascular disease was carried out in total population, including an examination of common risk factors.
Objective Based on the Isle of Youth Study (ISYS) data, determine prevalence of obesity and overweight, and their association with CKD, HTN, DM, and shared risk factors for all these conditions in total population of the Isle of Youth, Cuba.
Methods Phase 1: Population diagnosis (November 2004-April 2006): 96.6% of the Isle of Youth’s total population (80,117) was studied, including all ages and both sexes. Information was offered to the public, and written informed consent obtained. Screening was conducted by participant questionnaire including risk factors, physical measurements (weight, height, blood pressure and body mass index), and a single first-morning urine sample to determine the presence of vascular-renal damage markers – proteinuria and hematuria (Combur 10 Test, Roche), and microalbuminuria (Micral Test, Roche). When results were positive, serum creatinine was determined and glomerular filtration rate (GFR) estimated with Modification of Diet in Renal Disease (MDRD) formula for adults and Schwartz formula for children ‹15 years. Data obtained were analyzed to determine association of participants’ nutritional status with prevalence of chronic kidney disease, hypertension and diabetes mellitus, as well as a set of common risk factors.
Results Population ‹20 years: Obesity prevalence 3.2%; positive urine markers in 56.9% of obese and 8.9% of non-obese participants; positive albuminuria in 38% of obese and 3% of non-obese. Obese participants were found to be hyperfiltrating. DM prevalence was 9.5% in obese and 1.1% in non-obese participants. Population ≥20 years: Overweight, 31.3%; obese, 13.4%. Positive markers in normal-weight, overweight and obese individuals were 18.3%, 21.2% and 32.7%, respectively; microalbuminuria values increased with weight. Obese individuals were found to be hyperfiltrating. HTN prevalence in normalweight, overweight and obese individuals was 18.3%, 31.5%, and 51.0% respectively; DM rates were 2.8%, 5.2% y 11.3%, respectively.
Conclusion In Cuba, obesity poses significant risk for vascular and renal damage and should be the focus of increased prevention efforts.


REFERENCES

  1. Eknoyan G. A history of obesity, or how what was good became ugly and then bad. Adv Chron Kidney Dis. 2006; 13(4):421-27.

  2. Hossain P, Kawar B, Nahas ME. Obesity and diabetes in the developing world - A growing challenge. N Engl J Med. 2007; 356(9):973-77.

  3. Doyle M, Siegel R, Supe K. Stages of change and transitioning for adolescent patients with obesity and hypertension. Adv Chron Kidney Dis. 2006; 13(4):386-93.

  4. Wang Y, Chen X, Klag MJ, Caballero B. Epidemic of childhood obesity: Implications for kidney disease. Adv Chron Kidney Dis. 2006; 13(4):336- 51.

  5. Douglas Williams J, Tremblay MS, Katzmarzyk PT. Geographic and demographic variation in the prevalence of overweight Canadian children. Obes Res. 2003; 11:668-73.

  6. Katzmarzyk PT, Mason C. Prevalence of class I, II and III obesity in Canada. CMAJ. 2006; 174(2):156-7. Online table (www.cmaj.ca/cgi/ content/full/174/2/156/DC1) consulted Jan 8, 2008.

  7. Oqden CL, Carroll MD, Curtin LR, McDowell MA et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006; 295:1549-55.

  8. Encuesta Nacional de Salud y Nutrición. Informe de Salud México, 2001-2005. México, D.F. (MX): Secretaría de Salud; 2005.

  9. Christakis NA, Fowler JH. The spread of obesity in a large social network over 32 years. N Engl J Med. 2007; 357(4):370-79.

  10. United States Renal Data System 2005 Annual Data Report. Am J Kidney Dis. 2006; 47(1 suppl1):10.

  11. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol. 2001; 12:2753-58.

  12. Centers for Disease Control and Prevention. Prevalence of chronic kidney disease and associated risk factors - United States, 1999-2004. MMWR Morb Mortal Wkly Rep. 2007; 56(8):161-65.

  13. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki Ch, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004; 65:1870-76.

  14. Hsu C, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006; 144:21-28.

  15. Chalmers L, Kaskel FJ, Bamgbola O. The role of obesity and its bioclinical correlates in the progression of chronic kidney disease. Adv Chron Kidney Dis. 2006;13(4):352-64.

  16. National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002; 106:3143-3421.

  17. Chertow GM, Hsu Chy, Johansen KL. The enlarging body of evidence: obesity and chronic kidney disease. J Am Soc Nephrol. 2006; 17:1695-02.

  18. Bagby SP. Obesity-initiated metabolic syndrome and the kidney: A recipe for chronic kidney disease? J Am Soc Nephrol. 2004; 15:2775-91.

  19. Tanaka H, Shiohira Y, Uezu Y, Higa A, Iseki K. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int. 2006; 69:369- 374.

  20. Lastra G, Manrique C, Sowers JR. Obesity, cardiometabolic syndrome, and chronic kidney disease: the weight of the evidence. Adv Chron Kidney Dis. 2006;13(4):365-73.

  21. Weisinger JR, Kempson RL, Eldridge L, Swenson RS. The nephritic syndrome. A complication of massive obesity. Ann Int Med. 1974; 81:440- 47.

  22. Cohen AH. Massive obesity and the kidney. A morphologic and statistical study. Am J Pathol. 1975; 81:117-30.

  23. Charles J, Charles L, Grubb W. Glomerulomegaly and focal segmental glomerulosclerosis associated with obesity and sleep-apnea syndrome. Am J Kidney Dis. 1987;10(6):470-72.

  24. Kamblam N, Markowitz GS, Valeri AM, Lin J, D’Ágati VD. Obesity-related glomerulopathy: An emerging epidemic. Kidney Int. 2001; 59:1498- 09.

  25. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005; 293: 455-62.

  26. Almaguer López M, Herrera Valdés R, Chipi Cabrera J, et al. Design and methodology of the Isle of Youth community-based epidemiological study of CKD, cardio-cerebral vascular disease, hypertension, and diabetes mellitus (ISYS). MEDICC Review. 2007; 9(1):23-30.

  27. Ministerio de Salud Pública, Dirección Nacional de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2006. Havana: Ministerio de Salud Pública; 2007.

  28. Kannel WB, Feinleib M, McNamara PN, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidem. 1979; 110(3):281-90.

  29. Debs Pérez G, de la Noval García R, Dueñas Herrera A, et al. Prevalencia de factores de riesgo coronario en 10 de Octubre. Su evolución a los 5 años. Rev Cub Card Cir Card. 2001;15:14- 20.

  30. Franco M, Ordúñez P, Caballero B, et al. Impact of energy intake, physical activity, and population wide weight-loss on cardiovascular disease and diabetes mortality in Cuba, 1980- 2005. Am J Epid. 2007;19:1-7.

  31. Jiménez-Acosta S, Díaz-Sánchez ME, Barroso I, et al. Estado nutricional de la población cubana adulta. Rev Españ Nutr Comunit. 2005; 11:18- 26.

  32. Fawcett DW. Tejido adiposo. In:Tratado de histología. Ed. Interamericana, Madrid: McGraw- Hill; 1995.

  33. Chudek J, Adamczak M, Nieszporek T, Wiecek A. The adipose tissue as a source of vasoactive hormones and cytokines with a potential role in the pathogenesis of cardiovascular and renal diseases. Rev Port Nefrol Hipert. 2006; 20(2):81- 91.

  34. Hanley A, Wagenknecht L, D´Agostino RJ, Zinman B, Haffner S. Identificación de individuos con resistencia insulínica y disfunción de la célula beta utilizando definiciones alternativas del síndrome metabólico. Diabetes. 2003; 52:2740-47.

  35. Chen J, Muntner P, Hamm LL, Fonseca V, Batuman V, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol. 2003; 14:469-77.

  36. Srivastava T. Nondiabetic consequences of obesity on kidney. Pediatr Nephrol. 2006; 21:463- 70.

  37. Dandona P, Mohanty P, Ghanim H, et al. The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leucocytes lipid peroxidation, and protein carbonylation. J Clin Endocrinol Metab. 2001; 86:355-362.

  38. Eckardt K-U, Bernbardt W, William C, Wiesener M. Hypoxia-inducible transcription factors and their role in renal disease. Sem Nephrol. 2007; 27(3):363-72.

  39. Praga M, Morales E. Obesity, proteinuria and progression of renal failure. Cur Opin Nephrol Hypert. 2006; 15(5):481-86.

  40. Kaysen GA. Role of inflammation and its treatment in ESRD patients. Blood Purif. 2002; 20:70- 80.

  41. Johnstone DB, Holzman LB. Clinical impact of research on the podocyte slit diaphragm. Nat Clin Pract Nephrol. 2006; 2(5):271-82.

  42. Herrera Valdés R. Mecanismos de daño en la enfermedad glomerular y la repercusión túbulointersticial. In: Treviño Becerra A, editor. Tratado de Nefrología. Mexico City: Editorial Prado; 2003.




2020     |     www.medigraphic.com